Get started
Author

M. Aguado Sorolla

Observed institution: Hospital de Sant Pau
OpenAlex ID: A5067895749
503MO Real-world clinical and genomic characterization of gliomas: Predictive and prognostic insights
2023 · O. Mirallas, G. Velilla, et al. · Annals of Oncology · 1
PDF
122P Clinical impact of expanded genetic referral criteria in sarcoma patients: A single referral institution experience
2026 · A. Ramirez de Olano Galdona, M. Aguado Sorolla, et al. · ESMO rare cancers.
PDF
695P Molecular landscape of IDH1/2-mutant gliomas: A Spanish multicentric cohort
2025 · J.G. Yaringaño Cerna, O. Mirallas, et al. · Annals of Oncology
104P Systemic treatment outcomes in advanced leiomyosarcoma: Experience from a Spanish reference centre
2025 · M. Aguado Sorolla, R. Teres Lleida, et al. · ESMO Open
138P Germline pathogenic variants in newly diagnosed sarcomas: Prevalence and implications for clinical and preventive management - Experience of a Spanish National Reference Center
2025 · R. Teres Lleida, M. Aguado Sorolla, et al. · ESMO Open
PDF
1479P Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
2024 · P. Gallardo Melo, F. Bosma, et al. · Annals of Oncology
457P Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM)
2024 · J.G. Yaringaño Cerna, O. Mirallas, et al. · Annals of Oncology
367P Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study
2024 · P. Cerda Serda, B. Martin Cullell, et al. · Annals of Oncology
PDF
64P Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Centre (NCCN) guidelines for advanced gastrointestinal stromal tumors (GIST)
2024 · R. Teres Lleida, M. Aguado Sorolla, et al. · ESMO Open
72P Thrombosis in leiomyosarcoma: Characteristics, assessment of predictive scores and survival analysis
2024 · A. Romano Cardozo, M.A. Molina Pérez, et al. · ESMO Open
43P MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
2023 · D.A. Gomez Puerto, O. Mirallas, et al. · ESMO Open
PDF
1670P Tumoral and non-tumoral thrombosis associated with pancreatic ductal adenocarcinoma (PDAC): Survival impact, assessment of predictive scales and rethrombosis
2023 · A.R. Cardozo, R. Teres Lleida, et al. · Annals of Oncology
PDF
1938P Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Network (NCCN) guidelines for advanced soft tissue sarcomas (STS) and bone sarcomas (BS)
2023 · M. Aguado Sorolla, R. Teres Lleida, et al. · Annals of Oncology
PDF
1098P Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.
2022 · A. Piedra, A. Barba Joaquín, et al. · Annals of Oncology
1763P Real-world outcomes before and after the access to immune-checkpoint inhibitors (ICI) in advanced urothelial carcinoma (aUC)
2022 · J.C. Tapia, G. Anguera Palacios, et al. · Annals of Oncology
PDF
1552P Magnitude of clinical benefit of cancer drugs used in advanced soft tissue sarcomas and GIST
2021 · R. Teres Lleida, P. Cerda Serda, et al. · Annals of Oncology
412P Surgery and stereotactic ablative body radiotherapy for colorectal cancer lung oligometastases: One centre experience
2021 · A. Piedra-Cascon, A.C. Virgili Manrique, et al. · Annals of Oncology
1638P Are all leiomyosarcomas created equal? Clinical characteristics and experience of a single reference centre
2020 · R. Teres Lleida, B. Martin Cullell, et al. · Annals of Oncology
Works count: 18
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type